MAPT and Alzheimer disease: Overall, the 900 μg dose of ACI-35.030 demonstrated a stronger and earlier (73.7% responder rate at week 2), more stable and sustained capacity (responder rate was constantly above 70% at all time points) to evolve the antibody response over time toward the endogenous pathological Tau (ePHF) present in the brain of participants with AD.